Opposing roles of membrane and soluble forms of the receptor for advanced glycation end products in primary respiratory syncytial virus infection

Journal of Infectious Diseases

Volumn 205, Issue 8, 2012, Pages 1311-1320

  Miller, Allison L ^a   Sims, Gary P ^a   Brewah, Yambasu A ^a   Rebelatto, Marlon C ^a   Kearley, Jennifer ^a   Benjamin, Ebony ^a   Keller, Ashley E ^a   Brohawn, Philip ^a   Herbst, Ronald ^a   Coyle, Anthony J ^b   Humbles, Alison A ^a   Kolbeck, Roland ^a  

^a MEDIMMUNE   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; GAMMA INTERFERON; INTERFERON; INTERLEUKIN 10; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; VIRUS RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INFLAMMATION; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEIN FUNCTION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; VIRUS LOAD; WEIGHT REDUCTION; WILD TYPE;

ANIMALS; GLYCOSYLATION END PRODUCTS, ADVANCED; LUNG; MICE; MICE, KNOCKOUT; NOSE; PROTEIN ISOFORMS; RECEPTORS, IMMUNOLOGIC; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; VIRAL LOAD;

EID: 84859022943     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir826     Document Type: Article

References (47)

1. Perez-Yarza EG, Moreno A, Lazaro P, Mejias A, Ramilo O. The association between respiratory syncytial virus infection and the development of childhood asthma: a systematic review of the literature. Pediatr Infect Dis J 2007; 26:733-9.
2. Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med 2009; 360: 588-98.
3. Ramirez JA. RSV infection in the adult population. Manag Care 2008; 17(11 Suppl 12):13-15, discussion.
4. The World Health Organization. The global burden of disease. Geneva, Switzerland: WHO Press, 2004: 23.
5. Ko FW, Ip M, Chan PK, et al. Viral etiology of acute exacerbations of COPD in Hong Kong. Chest 2007; 132:900-8.
6. Ko FW, Ip M, Chan PK, et al. A 1-year prospective study of the infectious etiology in patients hospitalized with acute exacerbations of COPD. Chest 2007; 131:44-52.
7. Cameron RJ, de WD, Welsh TN, Ferguson J, Grissell TV, Rye PJ. Virus infection in exacerbations of chronic obstructive pulmonary disease requiring ventilation. Intensive Care Med 2006; 32:1022-9.
8. Camargo CA Jr, Ginde AA, Clark S, Cartwright CP, Falsey AR, Niewoehner DE. Viral pathogens in acute exacerbations of chronic obstructive pulmonary disease. Intern Emerg Med 2008; 3:355-9.
9. Seemungal T, Harper-Owen R, Bhowmik A, et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164:1618-23.
10. Borg I, Rohde G, Loseke S, et al. Evaluation of a quantitative real-time PCR for the detection of respiratory syncytial virus in pulmonary diseases. Eur Respir J 2003; 21:944-51.
11. Wilkinson TM, Donaldson GC, Johnston SL, Openshaw PJ, Wedzicha JA. Respiratory syncytial virus, airway inflammation, and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 173:871-6.
12. Santilli F, Vazzana N, Bucciarelli LG, Davi G. Soluble forms of RAGE in human diseases: clinical and therapeutical implications. Curr Med Chem 2009; 16:940-52.
13. Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ. HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol 2010; 28: 367-88.
14. Fehrenbach H, Kasper M, Tschernig T, Shearman MS, Schuh D, Muller M. Receptor for advanced glycation endproducts (RAGE) exhibits highly differential cellular and subcellular localisation in rat and human lung. Cell Mol Biol (Noisy-le-grand) 1998; 44:1147-57.
15. Katsuoka F, Kawakami Y, Arai T, et al. Type II alveolar epithelial cells in lung express receptor for advanced glycation end products (RAGE) gene. Biochem Biophys Res Commun 1997; 238:512-16.
16. van Zoelen MA, van der Sluijs KF, Achouiti A, et al. Receptor for advanced glycation end products is detrimental during influenza A virus pneumonia. Virology 2009; 391:265-73.
17. van Zoelen MA, Schouten M, de Vos AF, et al. The receptor for advanced glycation end products impairs host defense in pneumococcal pneumonia. J Immunol 2009; 182:4349-56.
18. Miller AL, Bowlin TL, Lukacs NW. Respiratory syncytial virus-induced chemokine production: linking viral replication to chemokine production in vitro and in vivo. J Infect Dis 2004; 189:1419-30.
19. Tekkanat KK, Maassab HF, Cho DS, et al. IL-13-induced airway hyperreactivity during respiratory syncytial virus infection is STAT6 dependent. J Immunol 2001; 166:3542-8.
20. Bueno SM, Gonzalez PA, Cautivo KM, et al. Protective T cell immunity against respiratory syncytial virus is efficiently induced by recombinant BCG. Proc Natl Acad Sci U S A 2008; 105:20822-7.
21. Fulton RB, Meyerholz DK, Varga SM. Foxp31 CD4 regulatory T cells limit pulmonary immunopathology by modulating the CD8 T cell response during respiratory syncytial virus infection. J Immunol 2010; 185:2382-92.
22. Hashimoto K, Mori S, Hashimoto Y, et al. DSCG reduces RSV-induced illness in RSV-infected mice. J Med Virol 2009; 81:354-61.
23. Hayes PJ, Scott R, Wheeler J. In vivo production of tumour necrosis factor-alpha and interleukin-6 in BALB/c mice inoculated intranasally with a high dose of respiratory syncytial virus. J Med Virol 1994; 42: 323-9.
24. Lee DC, Harker JA, Tregoning JS, et al. CD251 natural regulatory T cells are critical in limiting innate and adaptive immunity and resolving disease following respiratory syncytial virus infection. J Virol 2010; 84:8790-8.
25. Zhang W, Choi Y, Haynes LM, et al. Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice. J Virol 2010; 84:1148-57.
26. Graham BS, Bunton LA, Wright PF, Karzon DT. Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. J Clin Invest 1991; 88:1026-33.
27. Tregoning JS, Pribul PK, Pennycook AM, et al. The chemokine MIP1alpha/CCL3 determines pathology in primary RSV infection by regulating the balance of T cell populations in the murine lung. PLoS One 2010; 5:e9381.
28. Graham BS, Perkins MD, Wright PF, Karzon DT. Primary respiratory syncytial virus infection in mice. J Med Virol 1988; 26:153-62.
29. Liliensiek B, Weigand MA, Bierhaus A, et al. Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest 2004; 113:1641-50.
30. Lutterloh EC, Opal SM, Pittman DD, et al. Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection. Crit Care 2007; 11:R122.
31. Johnson TR, Hong S, Van KL, Koezuka Y, Graham BS. NK T cells contribute to expansion of CD81 T cells and amplification of antiviral immune responses to respiratory syncytial virus. J Virol 2002; 76: 4294-303.
32. Frommhold D, Kamphues A, Hepper I, et al. RAGE and ICAM-1 cooperate in mediating leukocyte recruitment during acute inflammation in vivo. Blood 2010; 116:841-9.
33. Chavakis T, Bierhaus A, Al-Fakhri N, et al. The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med 2003; 198: 1507-15.
34. Jewell NA, Vaghefi N, Mertz SE, et al. Differential type I interferon induction by respiratory syncytial virus and influenza a virus in vivo. J Virol 2007; 81:9790-800.
35. Ramaswamy M, Shi L, Monick MM, Hunninghake GW, Look DC. Specific inhibition of type I interferon signal transduction by respiratory syncytial virus. Am J Respir Cell Mol Biol 2004; 30:893-900.
36. McIntosh K. Interferon in nasal secretions from infants with viral respiratory tract infections. J Pediatr 1978; 93:33-6.
37. Guerrero-Plata A, Baron S, Poast JS, Adegboyega PA, Casola A, Garofalo RP. Activity and regulation of alpha interferon in respiratory syncytial virus and human metapneumovirus experimental infections. J Virol 2005; 79:10190-9.
38. Sung RY, Yin J, Oppenheimer SJ, Tam JS, Lau J. Treatment of respiratory syncytial virus infection with recombinant interferon alfa-2a. Arch Dis Child 1993; 69:440-2.
39. Pullerits R, Brisslert M, Jonsson IM, Tarkowski A. Soluble receptor for advanced glycation end products triggers a proinflammatory cytokine cascade via beta2 integrin Mac-1. Arthritis Rheum 2006; 54:3898-907.
40. Wang Y, Wang H, Piper MG, et al. sRAGE induces human monocyte survival and differentiation. J Immunol 2010; 185:1822-35.
41. Bucciarelli LG, Wendt T, Qu W, et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 2002; 106:2827-35.
42. Kislinger T, Tanji N, Wendt T, et al. Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 2001; 21:905-10.
43. Zhang H, Tasaka S, Shiraishi Y, et al. Role of soluble receptor for advanced glycation end products on endotoxin-induced lung injury. Am J Respir Crit Care Med 2008; 178:356-62.
44. Koch M, Chitayat S, Dattilo BM, et al. Structural basis for ligand recognition and activation of RAGE. Structure 2010; 18:1342-52.
45. Nakamura K, Yamagishi S, Adachi H, et al. Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease. Diabetes Metab Res Rev 2007; 23:368-71.
46. Nin JW, Ferreira I, Schalkwijk CG, et al. Levels of soluble receptor for AGE are cross-sectionally associated with cardiovascular disease in type 1 diabetes, and this association is partially mediated by endothelial and renal dysfunction and by low-grade inflammation: the EURODIAB Prospective Complications Study. Diabetologia 2009; 52:705-14.
47. Bopp C, Hofer S, Weitz J, et al. sRAGE is elevated in septic patients and associated with patients outcome. J Surg Res 2008; 147:79-83.